Hello NMPA: New English Website For China's Regulator, Inspection Scheme Bolstered
Executive Summary
China's main drug regulatory agency is hoping to tell its story to the world via a new English website, while the vaccines and other sectors are poised to see increasing quality inspections as the country builds up a new two-level scheme. Provincial reimbursement lists are also being halted.
You may also be interested in...
Hello NMPA: New Drug Approvals, Online Database And More
China grants approvals to Gilead’s HIV combo Biktarvy and Mitsubishi Tanabe Pharma’s Radicava in the latest batch of new product clearances. Meanwhile, a new online database for marketing authorization holders goes live.
Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement
China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.